|
Peter Barton Hutt is a partner specializing in food and drug law in the Washington, D.C. law firm of Covington & Burling. He served as Chief Counsel for the FDA from 1971-1975 and is the co-author of a casebook used to teach food and drug law throughout the country. Mr. Hutt currently serves on the Boards of Directors of several public and privately-held biotechnology companies, including CV Therapeutics, Inc. and Cognetix, Inc., and venture capital advisory boards, including Polaris Venture Partners and the Sprout Group. He has previously served as a director of other companies, including IDEC Pharmaceuticals Corporation (now Biogen IDEC Inc.) during its development of Rituxan®. Mr. Hutt has served on many advisory committees including the Advisory Committee to the Director of the National Institutes of Health (NIH), the NIH Advisory Committee to Review the Guidelines for Recombinant DNA Research, and five Office of Technology Assessment advisory panels. Washingtonian magazine has named Mr. Hutt one of Washington D.C.'s 50 best lawyers (out of more than 40,000) and one of Washington D.C.'s 100 most influential people. The National Law Journal has named him one of the 40 best health care lawyers in the United States and the European Counsel has called him the best FDA regulatory specialist in Washington, D.C. Mr. Hutt graduated from Yale University and Harvard Law School and earned a Master of Laws degree in Food and Drug Law from New York University Law School. | 